FDA grants Nanobiotix Fast Track designation for investigation of NBTXR3 in head and neck

As Biden invokes wartime powers to regulate AI, oncology braces for fundamental change

Invoking the Defense Production Act, President Joe Biden has ordered federal agencies and artificial intelligence companies to create safeguards and standards for the technology that has the capacity to uplift humankind as much as it can wreak unimaginable harm.

November 17, 2023

Vol.49 No.43

By Matthew Bin Han Ong

Conversation with The Cancer Letter

Paige’s Razik Yousfi: Biden has set expectations for AI, but details will come via federal guidelines

As a data scientist and software engineer, Razik Yousfi builds artificial intelligence models in health care. He started doing this 15 years ago, long before advanced chatbots catapulted AI into the layman’s consciousness.

November 17, 2023

Vol.49 No.43

By Matthew Bin Han Ong

White House

Biden intends to appoint W. Kimryn Rathmell as NCI director

President Joe Biden on Nov. 17 announced his intent to appoint W. Kimryn Rathmell as NCI director.

ODAC reviews two longest-running accelerated approvals as FDA weighs using its new authority

The FDA Oncologic Drugs Advisory Committee earlier this week was asked to review two of the slowest-moving confirmatory trials.

ESMO discussants urge physicians to prescribe lower dose of Amgen’s sotorasib

Experts in pharmacology and lung cancer urged physicians to prescribe the Amgen agent Lumakras (sotorasib) at the lowest tested dose—240 mg—instead of the four times higher dose of 960 mg recommended by the sponsor.

Integrating cancer care: the Advocate Health experience

As the third-largest nonprofit health system nationwide, Advocate Health treats nearly 50,000 new cancer cases annually. The integrated system has a unique opportunity to leverage its scale to advance complex cancer care and improve health outcomes across its various markets.

November 17, 2023

Vol.49 No.43

By Ruben A. Mesa and James L. Weese

FDA grants Nanobiotix Fast Track designation for investigation of NBTXR3 in head and neck

YOU MAY BE INTERESTED IN

As Biden invokes wartime powers to regulate AI, oncology braces for fundamental change

Paige’s Razik Yousfi: Biden has set expectations for AI, but details will come via federal guidelines

Biden intends to appoint W. Kimryn Rathmell as NCI director

ODAC reviews two longest-running accelerated approvals as FDA weighs using its new authority

ESMO discussants urge physicians to prescribe lower dose of Amgen’s sotorasib

Integrating cancer care: the Advocate Health experience

Renew today!

Subscriber content

Login